Dysplasia News and Research

RSS

Dysplasia is a term used in pathology to refer to an abnormality in maturation of cells within a tissue. This generally consists of an expansion of immature cells, with a corresponding decrease in the number and location of mature cells.

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Inovio Pharmaceuticals and the University of Pennsylvania have received a grant of $3.1 million from the National Institutes of Health (NIH) Director's Office to further fund Inovio's universal SynCon™ flu vaccine development.

30 Sep 2010

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.

29 Sep 2010

Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the Phase I clinical study assessing Inovio's PENNVAX-B DNA vaccine delivered using its proprietary electroporation technology in a preventive setting has fully completed the enrollment of 48 healthy volunteers. The multi-center study is being conducted by Inovio's clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites under a protocol designated HVTN-080.

21 Sep 2010

MVI agrees to provide fund for evaluating Inovio's malaria DNA vaccine candidate in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has agreed to provide follow-on funding to continue evaluation and development of Inovio's malaria DNA vaccine candidate in non-human primates.

15 Sep 2010

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18.

13 Sep 2010

Edimer Pharmaceuticals, CMC Biologics execute manufacturing contract to develop EDI200 recombinant protein

Edimer Pharmaceuticals and CMC Biologics today announce the execution of a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe.

10 Sep 2010

PennHIP radiographic method may hold potential to evaluate human susceptibility to hip dysplasia

A study comparing a University of Pennsylvania method for evaluating a dog's susceptibility to hip dysplasia to the traditional American method has shown that 80 percent of dogs judged to be normal by the traditional method are actually at risk for developing osteoarthritis and hip dysplasia, according to the Penn method.

4 Sep 2010

ECG-based screening for young footballers at risk of heart disease needs to be reviewed: Study

The screening process for young footballers at risk of heart disease needs to be re-evaluated. That is the conclusion of a recent study, which has shown that the common criteria used for assessment does not take into account the type and intensity of the exercise performed. The single most common cause of sudden death in competitive footballers is hypertrophic cardiomyopathy - a disease that thickens the heart muscle without any obvious cause.

31 Aug 2010

Queensway Carleton Hospital staff to protest against Liberal government's budget cuts

Staff of the Queensway Carleton Hospital represented by CUPE will protest at lunchtime today over $5,000,000 in budget cuts imposed by the provincial Liberal government.

24 Aug 2010

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has completed the nine (9) doses to be administered to the three (3) vanguard patients in the low dose group of its phase II cervical dysplasia clinical trial study.

19 Aug 2010

UMDNJ identifies direct link between phthalates in plastics and inflammation in newborns

Researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ) have identified a direct link between phthalates, the substances that make plastics more pliable and durable, and inflammation in newborns - and are encouraging more limited use of the plasticizers. Their paper, "Inflammatory Effects of Phthalates in Neonatal Neutrophils," appears in the August 2010 edition of the journal Pediatric Research.

21 Jul 2010

Hospital for Special Surgery named top hospital for orthopedics

Hospital for Special Surgery has been named the top hospital in the nation for orthopedics by U.S. News & World Report in its 2010 "America's Best Hospitals" issue. Once again the hospital ranked as a leader in rheumatology at number 3 in the nation. In addition, neurology was ranked at number 16.

15 Jul 2010

BARRX Medical closes $15 million Series D financing

BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.

14 Jul 2010

Researchers identify gene abnormality for most common congenital birth defect, clubfoot

Although clubfoot is one of the most common congenital birth defects, few genetic causes have been found. Now, researchers at Washington University School of Medicine in St. Louis have found what they believe to be the most common cause of inherited clubfoot yet discovered.

2 Jul 2010

InNexus develops IXS312 small protein fragment as topical therapy for AMD, diabetic retinal dysplasia

InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced that it has developed IXS312(VEGF), an antibody fragment with activity against the growth factor VEGF for planned use in ocular treatments.

30 Jun 2010

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports the successful completion of another clinical trial to validate the effectiveness of the company's technology for early identification and diagnosis of cervical cancer, in conventional cytological smears.

24 Jun 2010

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.

24 Jun 2010

Children get MRI tests for reasons unrelated to benign anomalies: Study

Pediatricians whose patients undergo "routine" brain MRIs need a plan to deal with findings that commonly reveal unexpected-but-benign anomalies that are unlikely to cause any problem, reports a research team led by Johns Hopkins Children's Center investigators.

14 Jun 2010

High frequency ventilation for preterm babies just as effective

A University of Sydney study of ventilation strategies has shown that high-frequency oscillatory ventilation (HFOV) for preterm babies gives the same outcomes as conventional ventilation (CV).

4 Jun 2010

CPAP treatment may be a better option for preterm infants

A national study involving a UT Southwestern Medical Center neonatologist provides new insight into how much oxygen preterm infants should receive as well as the optimal way to deliver it to them.

3 Jun 2010